Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors

NCT00485719 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00485719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2007
Completion date
September 30, 2012
Enrollment
83 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer